| Primary information |
|---|
| sequence ID | Seq_7302 |
| Peptide sequence | SLDRNLPSDSQDLGQHGLEEDFM |
| CancerPDF_ID | CancerPDF_ID2032, CancerPDF_ID9879, CancerPDF_ID9880, |
| PMID | 21136997,21533267,21533267 |
| Protein Name | Secretory granule proteoglycan core protein,Serglycin,Serglycin |
| UniprotKB Entry Name | SRGN_HUMAN,SRGN_HUMAN,SRGN_HUMAN |
| Fluid | Serum,Serum,Serum |
| M/Z | 2602.16056,873.71,868.4 |
| Charge | 1,3,3 |
| Mass (in Da) | NA,NA,NA |
| fdr | NA,NA,NA |
| Profiling Technique | LC-MS,LC-MS,LC-MS |
| Peptide Identification technique | LC-MS-MS/MS,LC/MS/MS,LC/MS/MS |
| Quantification Technique | LC-ESI-MS,Multiple Reaction Monitoring,Multiple Reaction Monitoring |
| Labelled/Label Free | Label Free,Label Free,Label Free |
| FDR | NA,1.49,1.49 |
| CancerPDF_ID | CancerPDF_ID2032, CancerPDF_ID9879, CancerPDF_ID9880, |
| p-Value | NA,NA,NA |
| Software | MASCOT(v. 2.2.01),MASCOT,MASCOT |
| Length | 23,23,23 |
| Cancer Type | Colorectal cancer,Lung adenocarcinoma,Lung adenocarcinoma |
| Database | SwissProt Database,Swissprot Database (57.4),Swissprot Database (57.4) |
| Modification | NA,Oxidation,NA |
| Number of Patients | 30 patients and 30 healthy controls,62 lung adenocarcinoma and 30 healthy control,62 lung adenocarcinoma and 30 healthy control |
| Regulation | NA,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal","Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" |
| Validation | Leave One out Cross validation,MRM-based validation of 19 candidates,MRM-based validation of 19 candidates |
| Sensitivity | NA,NA,NA |
| Specificity | NA,NA,NA |
| Accuracy | NA,NA,NA |
| Peptide Atlas | PeptideAtlas |
| IEDB | 526213
526214
|